Circulating Tumor DNA in High-Risk Localized Prostate Cancer
This study is looking at a new way to detect prostate cancer cells in the blood of men with high-risk localized prostate cancer. Researchers will collect blood samples before surgery (prostatectomy) to see if they can find circulating tumor DNA (ctDNA). This ctDNA is genetic material shed by cancer cells into the bloodstream. The study aims to see how well this method works to find ctDNA over a period of up to two years. You might be able to join if you are a man aged 18 or older with confirmed prostate cancer, have a good performance status (meaning you can perform daily activities), and are willing to provide blood samples. The study is currently unclear on its recruitment status and plans to enroll 24 participants.
- Study design
- This is an observational study, meaning participants will not receive an experimental treatment. It plans to enroll 24 participants.
- What's involved
- You would need to provide serial blood samples for the study.
- Compensation
- Not stated in the trial record.
- Follow-up
- The primary endpoint, ctDNA detection, will be measured for up to 2 years.
AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.
Circulating Tumor DNA in High Risk Localized Prostate Cancer
At a glance
Conditions
Where it's being run
1 sites across 1 statesStudy leadership
- Leonard J Appleman, MD, PhD · PRINCIPAL_INVESTIGATOR · UPMC Hillman Cancer Center
Who to contact
Opens a ready-to-send draft in your own email app — review before sending.
Do you actually qualify for this trial?
Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.
Inclusion
What this trial measures
- ctDNA detectionUp to 2 years
Detection of ctDNA by assay in blood collected prior to radical prostatectomy using the Vogelstein lab assay. This assay is a highly sensitive, tumor-informed method of detecting circulating free DNA (cfDNA) shed by solid tumors that has shown prognostic value for recurrence and predictive for benefit of adjuvant chemotherapy.